SAN DIEGO, Jan. 7, 2016 /PRNewswire/ -- In a series of five studies reporting results from analysis of over 5,000 patients presented today at the 2016 Genitourinary Cancers Symposium in San Francisco, researchers from multiple top academic institutions and GenomeDx Biosciences described new genomic understanding of biomarkers and drug targets using data obtained from the Decipher Genomic Resource Information Database (Decipher GRID™).
"These studies reflect the depth of knowledge and speed of innovation we believe is possible with Decipher GRID, our data sharing and collaborative research platform currently being used by clinician-scientists to advance new research in urologic cancers," said Doug Dolginow, M.D., Chief Executive Officer of GenomeDx. "Collaborative efforts between researchers from GenomeDx and multiple academic institutions are enabling the identification of trends in a way we couldn't before imagine thanks to the genomic data available through the Decipher GRID. That's good news for cancer research and ultimately, good news for patients."
Abstract 12: Efficacy of early and delayed radiation in a prostatectomy cohort adjusted for genomic and clinical risk
In a presentation highlighted as a top abstract of the conference, presented by Robert Den, M.D., assistant professor of radiation oncology and cancer biology at Thomas Jefferson University, data from Decipher GRID was used to further validate the Decipher Prostate Cancer Classifier as a predictive tool for identifying metastatic risk after prostate removal. In the study, prostate tumors were analyzed from 422 patients who had undergone radical prostatectomy at one of four institutions: Mayo Clinic, Durham VA Hospital, Johns Hopkins Medical Institution and Thomas Jefferson University. Results showed that patients with high Decipher and CAPRA-S scores were more likely to benefit from adjuvant and earlier radiation therapy, while patients with low Decipher and CAPRA-S scores had low rates of metastasis even when observed without any hormone or radiation therapy.
Abstract 98: The frequency of druggable targets in localized prostate cancer: initial analysis from the Decipher GRID
In a study presented by GenomeDx researchers, Decipher GRID demonstrated initial capabilities to evaluate, on a systematic population level, the expression of genes that may be targeted with existing cancer therapies. The study used global RNA expression data from Decipher GRID to assess the expression patterns of 35 genes from six biological pathways in a total of 2,293 patients. The study looked at the prevalence of these genes in the population of men who received the Decipher test between January and September 2015. These results demonstrate how Decipher and Decipher GRID may be useful for identification of suitable candidates for targeted therapy clinical trials earlier in the localized disease setting in men most at risk of developing metastasis.
Abstract 256: The relationship of B7H3 expression to androgen and prostate cancer outcomes in a large natural history cohort of men undergoing prostatectomy
In a study presented by Ashley Ross, M.D., Ph.D., associate professor of urology and oncology at Johns Hopkins School of Medicine, researchers utilized the Decipher GRID to investigate the role of the immunomodulatory marker B7H3 in predicting prostate cancer outcomes and its relationship to androgen receptor (AR) activity. In 905 patients treated at Johns Hopkins and Mayo Clinic, researchers found that higher B7H3 expression was correlated to AR activity as well as being associated with higher Gleason Scores and tumor stage (p<0.01), and higher likelihood of BCR, metastasis and prostate cancer specific mortality (p<0.001).
Abstract 106: Development and validation of an ADT resistance signature that predicts adjuvant hormone treatment failure
In a presentation delivered by R. Jeffrey Karnes, M.D., associate professor and vice chair in urology at Mayo Clinic, expression profiles from 1,023 patients treated with radical prostatectomy were used to create a signature for androgen deprivation therapy (ADT) resistance. The signature was tested across multiple validation cohorts, showing accurate prediction of metastasis in patients receiving early ADT. A significant treatment interaction was observed for this signature in multivariable interaction analysis, suggesting that this signature may be useful for identification of patients not likely to benefit from early ADT. The study authors concluded that these patients may be ideal candidates for the testing of novel systemic agents to treat prostate cancer.
Abstract 303: Deciphering the genomic fingerprint of small cell prostate cancer with potential clinical utility
In a study presented by GenomeDx and researchers from Johns Hopkins, expression profiles of 617 prostate cancer patients including rare cases of small cell prostate cancer were obtained from the Decipher GRID and used to create a small cell genomic score (SCGS). Patients with small cell prostate cancer have distinct genomic profiles from other forms of prostate cancer. In validation cohorts using 493 patients with prostate adenocarcinoma (the predominant histologic variant of the disease), results showed that high SCGS scores were predictive of rapid metastasis following prostate removal. The results support the development of the genomic fingerprint to better identify patients at diagnosis who likely will require more intensive, nonstandard approaches to treatment than the majority of men diagnosed with prostate cancer.
About Decipher® Prostate Cancer Classifier
Decipher® is a genomic test that provides an assessment of tumor aggressiveness and is used by radiation oncologists and urologists to help them determine who to treat and how to treat them in order to offer the most effective and least harmful course of therapy. Decipher offers valuable insight that is distinct from clinical measures of risk including PSA and Gleason score. Studies of thousands of patients from leading cancer centers, published in more than 20 peer-reviewed journals, demonstrate that Decipher can accurately predict metastatic disease, identify patients most likely to benefit from therapeutic intervention, and lead to significant cost-savings for healthcare systems by reducing unnecessary procedures. Decipher is covered by Medicare and multiple private insurance plans in the US representing over 190 million covered lives.
Learn more at www.DecipherTest.com
About Decipher GRID™
The Decipher Genomic Resource Information Database (Decipher GRID™) is the world's largest genomic expression data sharing program in urologic oncology created to enable improvements to precision medicine in patient care. GRID unifies a patient's whole genome data with clinical outcomes from thousands of patients evaluated with Decipher®, providing unprecedented data sharing capabilities. Ultimately, GRID seeks to use patient tumor genomic information to better match an individual to a targeted therapy with the highest likelihood of providing a benefit. The Decipher GRID program is rapidly expanding as major cancer centers partner with GenomeDx to access the database to advance their understanding of urologic cancers through the analysis of large amounts of genomic data.
Learn more at www.DecipherGRID.com
About GenomeDx Biosciences
GenomeDx Biosciences is a genomic information company changing the landscape of urologic cancer patient care with innovative genomic solutions that empower physicians and patients to make more informed decisions about patient treatment. Using advanced cloud-based bioinformatics to mine vast amounts of genomic data, the company develops and commercializes proprietary clinical tests that provide actionable information to answer key clinical questions in patient management. GenomeDx's Decipher® is a genomic test that provides an assessment of tumor aggressiveness and is used by urologists and radiation oncologists to help them determine who to treat and how to treat them in order to offer the most effective and least harmful course of therapy. In collaboration with leading medical centers GenomeDx is building Decipher GRID™, the world's largest genomic expression data sharing program in urologic oncology created to enable improvements to precision medicine in patient care. GenomeDx is based in San Diego, California and Vancouver, British Columbia.
Learn more at www.GenomeDx.com